Article Information
History
- December 30, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Cong Zeng1,2,#,
- John P. Evans1,2,3,#,
- Karthik Chakravarthy4,#,
- Panke Qu1,2,
- Sarah Reisinger5,
- No Joon Song4,
- Mark P. Rubinstein4,
- Peter G. Shields5,*,
- Zihai Li4,* and
- Shan-Lu Liu1,2,6,7,*
- 1Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA
- 2Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
- 3Molecular, Cellular and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA
- 4Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH43210, USA
- 5Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Columbus, OH 43210, USA
- 6Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210, USA
- 7Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA
- ↵*Corresponding Authors: Liu.6244{at}osu.edu, Zihai.Li{at}osumc.edu, Peter.Shields{at}osumc.edu
↵# Equal contribution
Posted December 30, 2021.
COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with Cancer
